XML 25 R13.htm IDEA: XBRL DOCUMENT
v3.25.1

Concentration of Credit Risk and Current Expected Credit Losses | 3 Months Ended
--- | ---
Mar. 31, 2025
Risks and Uncertainties [Abstract] |
Concentration of Credit Risk and Current Expected Credit Losses | Note 5. Concentration of Credit Risk and Current Expected Credit Losses In November 2009, we entered into a collaboration and license agreement with Novartis Pharmaceutical International Ltd. ("Novartis"). In December 2009, we entered into a license, development and commercialization agreement with Eli Lilly and Company ("Lilly"). The above collaboration partners comprised, in aggregate, 16% and 19% of the accounts receivable balance as of March 31, 2025 and December 31, 2024, respectively. For further information relating to these collaboration and license agreements, refer to Note 8. In November 2011, we began commercialization and distribution of JAKAFI and in October 2021, we began commercialization and distribution of OPZELURA. Our product revenues are concentrated in a number of customers for these products. The concentration of credit risk related to our JAKAFI and OPZELURA product revenues is as follows:
| Percentage of Total Net Product Revenues for the Three Months Ended |  |
| March 31, |  |
| 2025 |  | 2024 |  |  |  |
Customer A | 14 | % |  | 17 | % |  |  |  |
Customer B | 10 | % |  | 11 | % |  |  |  |
Customer C | 20 | % |  | 18 | % |  |  |  |
Customer D | 14 | % |  | 12 | % |  |  |  |
Customer E | 9 | % |  | 10 | % |  |  |  |
We are exposed to risks associated with extending credit to customers related to the sale of products. Customers A, B, C, D and E comprised, in the aggregate, 51% and 52% of the accounts receivable balance as of March 31, 2025 and December 31, 2024, respectively. The concentration of credit risk relating to our other product revenues or accounts receivable is not significant. We assessed our collaborative and customer receivable assets as of March 31, 2025 according to our accounting policy for applying reserves for expected credit losses, noting minimal history of uncollectible receivables and the continued perceived creditworthiness of our third party sales relationships, upon which the expected credit losses were considered de minimis. As of March 31, 2025 and December 31, 2024, we had no allowance for doubtful accounts.

X
- Definition The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContent + Details
Name: | us-gaap_ConcentrationRiskDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RisksAndUncertaintiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration